News Release

IC-medtech licenses promising cancer therapeutic from Summa Health System

Business Announcement

Summa Health System

(Akron, Ohio) In September 2001, researchers at Summa Health System in Akron, Ohio reported that moderate doses of the vitamins C and K3 were eliminating many types of cancer cells including prostate, bladder, renal and ovarian. Today, only three years later, the results of Summa's cancer research is being licensed and under a new name, ApatoneTM. Clinical trials of the drug could begin as soon as next month at Summa Health System and other hospitals across the nation.

Indian Creek Medical Technologies, LLC has exclusively licensed Apatone, the novel anti-cancer therapeutic treatment first discovered by James M. Jamison, Ph.D. and Jack L. Summers, M.D, Ph.D, both of Summa Health System, in collaboration with Jacques Gilloteaux, DSc, and Henryk Taper, M.D., Ph.D. of Brussels, Belgium. The Summa team has been working collaboratively with Gilloteaux and Taper for nine years conducting extensive experimentation and now Summers and Jamison are excited by this next step with IC-MedTech.

"What is so significant about our study is that through out research of cancer cells, we have discovered a new form of cell death, never before reported," said Summers.

"We found early on that the combination of vitamins C and K3 seek out tumor cells and appear to leave normal cells unaffected," Summers explained. "The dying cells undergo a new flow of self-destruction in which the cell literally cuts itself into small pieces. This discovery was the first of its kind and to this point, cells were considered to die only by apoptosis (programmed cell death) or necrosis (toxic cell death or injury.)"

According to Tom Miller, CEO of IC-MedTech, his company is excited about the possibilities this drug could bring to cancer patients. "The research is substantial and shows that Apatone leverages a novel mechanism of action that shows strong promise as a clinical candidate to be developed for a variety of cancers."

A practical version of the chemo-adjunct based on low toxicity compounds to improve safety has been developed for use in clinical trials which are already underway. The treatment can be administered by intravenously (through a vein), intraperitoneally (through abdomen) or orally and it has been shown to enhance the performance of at least six different chemotherapeutic drugs (adriamycin, asparaginase, cyclophosphamide, 5-fluorouracil, oncovin and procarbazine).

Results of the research have been presented in more than 100 papers, abstracts and presentations with more than forty peer reviewed articles appearing in such publications as Cancer, Cancer Research, Anticancer Research, Cancer Chemotherapy and Pharmacology, Life Sciences, Journal of Nutrition, Tissue and Cell, Biochemical Pharmacology, Journal of Scanning Microscopy, Microscopy and Microanalysis and other.

###

About IC-MedTech
Founded in 2004, IC-MedTech is dedicated to the development of novel technologies and biotherapeutics to treat cancer and improve human health. IC-MedTech is currently developing Apatone together with a prognostic SADA (Serum Alkaline DNase Activity) test kit to enhance clinical treatment of a wide variety of cancers. For more information email info@ic-medtech.com.

About Summa Health System
Summa Health System is one of the largest organized delivery systems in Ohio. Encompassing a network of hospitals, community health centers, a health plan, a physician-hospital organization, research and a foundation, Summa is nationally renowned for excellence in patient care and for exceptional approaches to health care delivery. Summa's clinical services are consistently recognized by U.S. News and World Report, Solucient and Healthgrades. For more information, visit www.summahealth.org.

Note to Reporters and Editors: Dr. Jack Summers and Dr. James Jamison from Summa Health System and Tom Miller from IC-MedTech are available for interviews. Call Heather Phillips, Public Relations Manager from Summa to schedule an interview.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.